New Gene Mutation Associated with Fanconi Anemia
|
By LabMedica International staff writers Posted on 25 Jul 2017 |

Image: The enzyme E3 ubiquitin ligase (RFWD3) helps target other proteins on single-stranded DNA for degradation. B: Cells lacking RFWD3 show DNA repair defects (Photo courtesy of Julius-Maximilians-Universität).
Fanconi anemia is a rare genetic disease characterized by bone marrow failure heralded by low platelet counts and unusually large red blood cells. Mutations in over 20 genes have been identified as causative for Fanconi anemia, which encode proteins commonly involved in DNA repair mechanisms.
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Safeguarding of the genome is essential for the suppression of oncogenesis and for stem cell maintenance in many organisms, and is warranted by DNA repair mechanisms. If they fail on a genetic basis, DNA repair disorders occur and Fanconi anemia (FA) is such a rare human genomic instability disease.
Scientists at the Julius-Maximilians-Universität (Würzburg, Germany) reports classical Fanconi anemia symptoms in a 12-year-old individual without mutations in any of the known Fanconi anemia genes. The patient presented with congenital abnormalities characteristic of FA and had a typical FA phenotype and compound heterozygous mutations in the E3 ubiquitin ligase (RFWD3).
The team used various techniques in the study including DNA sample preparation, polymerase chain reaction (PCR), Sanger sequencing, and whole exome sequencing, on a HighSeq2000 instrument. Other methods used were generation of stable lentiviral producer lines and transduction of adherent cells, DT40 gene targeting, cell cycle, cell survival, and chromosomal studies, where cell numbers were determined using a Nucleo Counter NC-250. Immunofluorescence studies were analyzed on a BIOREVO BZ-9000 microscope.
Sequencing of this individual's genome detected mutations in both alleles of the gene RFWD3, which encodes an enzyme that helps target other proteins on single-stranded DNA for degradation. This process is impaired in patient's cells, which rendered them more sensitive to chromosome breakage and DNA damage, compared to cells from healthy individuals. Other cells either lacking RFWD3 or genetically engineered with the patient's missense mutation showed similar DNA repair defects, which were rescued by expression of wild-type RFWD3. Together, these findings support the identification of RFWD3 as a Fanconi anemia gene. The study was published on July 10, 2017, in the Journal of Clinical Investigation.
Related Links:
Julius-Maximilians-Universität
Latest Molecular Diagnostics News
- Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
- New AI Tool Improves Detection of Genetic Causes in Rare Disorders
- Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
- Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers
- New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
- First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
- Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
- New Respiratory Panel Expands Pathogen Detection to 25 Targets
- Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
- Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
- Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
- Blood Test Helps Guide Treatment in Older Women with Breast Cancer
- Rapid Host-Response Test Distinguishes Bacterial and Viral Infections in Minutes
- Liquid Biopsy Method Pinpoints Disease Source From a Single Drop of Blood
- Study Reveals Widespread Errors in Gene Variant Naming
- New Blood Test Aims to Transform Liver Cancer Surveillance
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








